



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Patent Application of**  
**Thomas BRODIN et al.**  
**Application No.: 10/088,639**  
**Filed: March 20, 2002**  
**For: NOVEL COMPOUNDS**

Group Art Unit: 1645  
Examiner: Unassigned  
Confirmation No.: 715

RECEIVED  
AUG 25 2003  
TECH CENTER 1600/2900

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

**BURNS, DOANE, SWECKER & MATHIS, L.L.P.**

Date: August 22, 2003

By: Deborah H. Yellin  
Deborah H. Yellin  
Registration No. 45,904

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620



Patent  
Attorney's Docket No. 003300-920

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
Thomas BRODIN et al. ) Group Art Unit: 1645  
Application No.: 10/088,639 ) Examiner: Unassigned  
Filed: March 20, 2002 ) Confirmation No.: 7152  
For: NOVEL COMPOUNDS )

RECEIVED

AUG 25 2003

TECH CENTER 1600/2900

SECOND  
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b) no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: August 22, 2003

By: 

Deborah H. Yellin  
Registration No. 45,904

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Substitute for forms 1449A/PTO &amp; 1449B/PTO

ATTORNEY'S DKT NO.  
003300-920APPLICATION NO.  
10/088,639SECOND INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Thomas BRODIN et al.FILING DATE  
August 20, 2003GROUP  
1645

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

RECEIVED

AUG 25 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Jerome DECOSSE et al., "Colorectal Cancer: Detection, Treatment, and Rehabilitation." CA Cancer J. Clin. Vol. 44, No. 1, January/February 1994, pp. 27-42. American Cancer Society, Atlanta, GA.
	G. RIETHMÜLLER et al., "Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial." Journal of Clinical Oncology, Vol. 16, No. 5 (May), 1998, pp. 1788-1794. American Society of Clinical Oncology, Alexandria, VA.
	Joseph A. KUHN et al., "Monoclonal Antibodies and Colorectal Carcinoma: A Clinical Review of Diagnostic Applications." Cancer Investigation, 12(3), 1994, pp. 314-323. Marcel Dekker, Inc., New York, NY.
	Jesper TORDSSON et al., "Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections." Journal of Immunological Methods, 210 (1997), pp. 11-23. North Holland Publishing, Amsterdam, Holland.
	L. AUJAME et al., "High affinity human antibodies by phage display." Human Antibodies, 1997, Vol. 8, 4, pp. 155-168. IOS Press, Amsterdam, Holland.
	Robert K. CLARK, et al., "Immunohistochemical Analysis of Antiserum from Rhesus Monkeys Immunized with Human Colon Carcinoma." Cancer Research, 49, July 1, 1989, pp. 3656-3661. American Association for Cancer Research, Baltimore, MD.
	Alan P. LEWIS, et al. "Cloning and Sequence Analysis of $\kappa$ and $\gamma$ Cynomolgus Monkey Immunoglobulin cDNAs," Developmental and Comparative Immunology, Vol. 17, 1993, pp. 549-560. Pergamon Press Ltd., Oxford, UK.
	Thomas N. BRODIN et al. "Man-made superantigens: Tumor-selective agents for T-cell-based therapy." Advanced Drug Delivery Reviews 31 (1998) pp. 131-142. Elsevier Science B.V., Amsterdam, Holland.
	Mikael DOHLSTEN et al., "Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell-based tumor therapy." Proc. Natl. Acad. Sci USA, Vol. 91., September 1994, Immunology, pp. 8945-8949. National Academy of Sciences, Washington, D.C.
	Changnian LIU, et al., "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids." Proc. Natl. Acad. Sci USA, Vol. 93, August 1996, Medical Sciences, pp. 8618-8623. National Academy of Sciences, Washington, D.C.

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.